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Significance of autoimmune reactions to pancreatic juice in 
Crohn's disease 
W. STÖCKER, Μ. OTTE AND P. C. SCRIBA 
Autoantibodies to exocrine pancreas (Pab) have been detected by indirect 
immunofluorescence in sera of patients with Crohn's disease (CD). High 
titres were frequent in CD, but could neither be recorded in ulcerative colitis 
nor in healthy subjects1. Pab in CD were as conspicuous as autoantibodies 
to intestinal goblet cells (Gab) in ulcerative colitis (UC) and other autoan­
tibodies in proven autoimmune diseases. The possible implication of pan­
creatic immunity in the pathogenesis of CD was discussed2. Results of 
additional studies enhance the significance of these observations. 
The association of Pab with CD could be verified by examination of new, 
larger collectives consisting of 150 patients with CD, 164 patients vith UC 
and 100 healthy control persons (Co) 3. Pab were predominant in CD (CD 
35%, UC 2%, Co 0%). High Pab-titres were only detectable in CD (1:100 
or higher in 30% of 150 patients). On the contrary, Gab were confrmed to 
be an exclusive marker for UC (CD 0%, UC 26%, Co 0%). 
The prevalence of Pab and Gab was determined in the sera of the patients' 
family members4 who are assumed to carry an elevated risk for developing 
chronic inflammatory bowel disease. Since none of 185 healthy a5p£äfing 
first degree family members exhibited Pab or Gab, these antibodies seem to 
be disease-specific and do not yet indicate a disposition for C D or UC. 
It was possible to isolate the CD-related autoantigen from pancrettic juice. 
The antigen was shown to be a macromolecule different from furctionally 
active trypsin, chymotrypsin, amylase and lipase, and it could neutnlize Pab 
of each positive CD-serum5. 
The autoimmune reactions in CD differed fundamentally frcm those 
observed in disorders of the pancreas: Pab were rare in chronic (2 o^  51) and 
acute (3 of 26) pancreatitis, their titres were low and did not exceed :32, they 
consisted only of IgA (CD: IgG or IgG + IgA) and could not be neutralized 
by the CD-related autoantigen6. 
A number of sera contained Pab or Gab with only one type of ligit chains, 
kappa or lambda. This uneven distribution speaks in favour of an olgoclonal 
382 
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antibody response and possibly indicates that the corresponding autoimmune 
reactions are phenomena of primary significance—a secondary immunization 
against pancreatic or goblet cell antigens in the course of CD or UC seems 
to be excluded7. 
In Crohn's disease, the bowel may have developed a state of hyper-
sensitivity against a physiologically occurring component of pancreatic juice. 
Pancreatitis is not predominant in CD since the bulk of autoantigens comes 
into contact with the immune system only outside the pancreas. As with other 
autoimmune diseases, the cause of sensibilization cannot yet be explained, 
and further investigations are required to completely reveal the etiology of 
CD. 
Determination of Pab is of great diagnostic value. In combination with 
Gab, they permit the diagnosis of CD or UC in one third of patients with 
chronic inflammatory bowel disease. 
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